Omenn Syndrome can Occur during Enzyme Therapy for Adenosine Deaminase Deficiency
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01764-z ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Elizabeth M Forbes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunopathology, Pathology Queensland, Herston, Australia. Elizabeth.forbes@health.qld.gov.au. Hauptthemen laut MEDLINE: Adenosine Deaminase, Severe Combined Immunodeficiency. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunopathology, Pathology Queensland, Herston, Australia. Elizabeth.forbes@health.qld.gov.au.
- Queensland Paediatric Immunology and Allergy Service, Queensland Childrens' Hospital, South Brisbane, Australia.
ORCID-Profile: Elizabeth M Forbes, Peter B McNaughton
Zitieren
APA
Forbes, E. M., & McNaughton, P. B. (2024). Omenn Syndrome can Occur during Enzyme Therapy for Adenosine Deaminase Deficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01764-z
Vancouver
Forbes EM, McNaughton PB. Omenn Syndrome can Occur during Enzyme Therapy for Adenosine Deaminase Deficiency. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01764-z
BibTeX
@article{Forbes2024,
author = {Forbes, Elizabeth M and McNaughton, Peter B},
title = {Omenn Syndrome can Occur during Enzyme Therapy for Adenosine Deaminase Deficiency},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01764-z}
}
EUVIMED